AMD diagnostic imaging
Patients are unaware they have a ticking time bomb in their eyes


Sean Henahan
Published: Tuesday, March 28, 2017

Patients are unaware they have a ticking time bomb in their eyesICG angiography Why not use ICG angiography to follow patients? That approach is expensive, invasive, time consuming, resource intensive, and until recently, such cases didn't have an intervention, he noted. Rather, Dr Rosenfeld and colleagues used a novel swept source OCT angiography system to look for subclinical CNV. The prototype from Carl Zeiss Meditec performed a 3mm X 3mm rraster scan centered on the fovea and repeated each B-scan 4 times, with 300 A-scans per B-scan, and 300 B-scan positions, for a total of 360,000 A-scans. Using a special decorrelation algorithms, the B-scans were compiled to provide en face flow images of the retina and choroid. The optical microangiographic approach known as OMAG provided provided the microvascular flow information and different layers were segmented, which included the whole retina, the inner or superficial retina layer or plexus, the middle or deep retinal plexus, and the outer avascular retinal layer. Another layer from the outer retinal layer to the choriocapillaris, known as the ORCC layer, was also created since this is where most of the choroidal neovascularization can be found. Subsequent clinical research (Ophthalmology, Roisman et al, Volume 123, Issue 6, 1309–1319) confirmed that the system could detect CNV lesions before they started leaking. Subsequent follow-up of 103 patients with wet AMD in one eye and dry AMD in the other revealed a prevalence of about 18% for these subclinical lesions, with an estimated rate of conversion to exudation of about 16% at one year, but longer follow-up is underway. “This is a new stage of non-exudative AMD. We call it non-exudative neovascular AMD. I think we can find these patients easily with SS-OCTA and we need to follow them closely. Ongoing studies are looking at prevalence, incidence, and onset of exudation. For now, in addition to close follow-up, we do not recommend anti-VEGF treatment,” he concluded. “I never treat asymptomatic patients. I educate my patients, I emphasize the need for vision monitoring at home, and I enlist them to be stewards of their own vision. In addition, if we start treatment in the absence of fluid, what’s our endpoint?,” Rosenfeld stated. prosenfeld@med.miami.edu
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.